$38.00
▼ -0.9% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Edgewise Therapeutics (EWTX) Trades At A Rich P B, Is The Premium Justified?
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Overview
52-week range
$12
$41
90% of range
Avg surprise (last 3)
+10.5%
Avg reaction (last 2)
-1.3%
50% positive
Latest IV / EM
71%
EM ±16.3% · $38 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.46 | $-0.50 | +8.0% | -7.0% | -3.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.39 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.34 | $-0.42 | +19.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.43 | $-0.45 | +4.4% | — | +1.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.36 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.34 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.33 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.34 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.48 | -$0.34 | -41.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-54M | — | $-47M | $-43M | $-46M | — | $-40M | $-38M |
| Net income | $-49M | — | $-41M | $-36M | $-41M | — | $-34M | $-31M |
| EPS (diluted) | $-0.46 | — | $-0.39 | $-0.34 | $-0.43 | — | $-0.36 | $-0.34 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $33M | $61M | $46M | $43M | $50M | $42M | $45M | $43M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $510M | $543M | $574M | $603M | $443M | $475M | $499M | $519M |
| Total assets | $519M | $553M | $583M | $613M | $454M | $487M | $511M | $532M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $25M | $30M | $25M | $24M | $25M | $28M | $22M | $21M |
| Total equity | $493M | $522M | $559M | $589M | $430M | $459M | $489M | $510M |